HIV PEPTIDES, ARTIFICIAL HIV ANTIGENS AND IMMUNOASSAY KITS

Abstract: An artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of an HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine residues, which has been formed by a chemical oxidation step, is described. Furthermore, an artificial antigen which reacts with antibodies induced by an HIV is described. Said antigen mainly consists of an artificial peptide according to the invention. Additionally, a method of detecting antibodies induced by an HIV in a sample of body fluid, wherein said sample is subjected to an immunoassay, especially ELISA, and wherein an artificial antigen according to the invention is used as a diagnostic antigen, is described. A diagnostic immunoassay kit for said method is also described. Finally, a vaccine composition comprising, as an immunizing component, at least one antigen according to the invention, is described.

Description: HIV peptides, artificial HIV antigens and immunoassay kits. The present invention relates to artificial peptides having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comp¬ rising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cystei¬ ne residues which has been formed by a chemical oxida¬ tion step. The invention also relates to artificial antigens, which react with antibodies induced by a HIV, a method of detecting antibodies induced by a HIV in a sample of body fluid, a diagnostic immunoassay kit for said method, and a vaccine composition compri¬ sing, as an immunizing component, at least one antigen of the invention. Background and Prior Art The acquired immunodeficiency syndrome (AIDS) is a sexually transmitted disease that can also be trans¬ mitted through contaminated blood or blood products. It is caused by human immunodeficiency virus (HIV, previously called HTLV-III) which infects and is latently harboured in T4-lymphocytes and onocytes (Wong-Staal, F. and Gallo, R.C.: Human T-lymphotropic retroviruses. Nature 317:395-403, 1985). The chronically HIV-infected individual may in turn transmit HIV, most often by sexual contact. During infection, the immune response deteriorates and AIDS develops in 50-70% of the cases. The fate for the remainder of infected persons is not yet known. When AIDS develops it is lethal and characterised by opportunistic infection, Kaposi sarcoma, other tumors and/or neurological disease. To diagnose an HIV infection, virus is isolated or the antibody response is measured. Virus isolation is successful in 30-50% of asymptomatic HIV infected persons, and in 90-100% of patients who developed AIDS. The antibody response is composed of immuno- globulins directed to the various structural and enzy¬ matic components of HIV. They include the virus envelope proteins glycoprotein (gp)120, the transmembrane protein gp41 and their precursor gplβO, the interior structural group antigens p24, 17 and 7/9 and their precursor p 55, the enzymes reverse transcriptase (RT) p65/51 and endonuclease p32 and protease. Antibodies to pro- teins of the regulatory regions of the HIV genome also develop. The correct identification of an HlV-in- fected person depends on the type(s) of immunoglobulin (Ig) he produces and on the correct composition of antigens used in the immunoassay. One common way to establish a diagnosis through antibody detection is to screen serum samples by enzyme- -linked immunosorbent assay (ELISA) (Sarngadharan, M.G,, Popovic, M. , Bruch, L. r Schύpbach, J. and Gallo, R.C. : Antibodies reactive with human T-lymphotropic retrovi- ruses (HTLV-III) in the serum of patients with AIDS. Science 224:506-508, 1984; Schtipbach, J. , Haller, 0., Vogt, M. , Ltithy, R. , Joller, H. , Oelz, 0., Popovic, M. , Sarngadharan, M.G. and Gallo, R.C: Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. The New Engl. J. Med. 312:265-270, 1985). Wells of microplates coated with viral antigens are reacted with the serum samples under investigation, washed, and antihuman Ig added. The latter reagent is labelled with an enzyme. After washing, the enzyme labelled antihuman Ig remains only if specific antiviral Ig was present in the serum sample. It is visualized by addition of a substrate for the enzyme and the color reaction quantified in a spectro- photometer. To verify this positive ELISA reaction, the serum sample is then added to e.g. Western blots which contain electrophoretically separated virus subcomponents. An immunoreaction on the Western blot will show whether Ig is reactive with the bands charac- teristic of viral subcomponents. Usually two different and characteristic bands are required to establish a definite diagnosis of HIV antibody. The reliability of HIV antibody detection is dependent on the reagents of the ELISA plate. Lysates of infected cells may contain cellular contaminants, causing false positive serological reactions (Saag, M.S. and Britz, J. : Asymptomatic blood donor with a false - positive HTLV-III western blot. The New Engl. J. Med. 314:118, 1985, Martin, P.W., Burger, D.R. , Caouette, S. and Goldstein, A.S.: Importance of confirmatory tests after strongly positive HTLV-III screening tests. The New Engl. J. Med. 314:1577, 1986). Viral lysates usually have an over-representation of gag proteins and less envelope proteins which may cause false nega¬ tive reactions. In addition to native viral lysates, recombinant-produced polypeptides have been produced (Ghrayeb, J. , Kato. I., McKinney, S., Huang, J.J., Chanda, P.K., Ho. D.D., Sarngadharan, M.G., Chang, T.W. and Chang, N.T. : Human T-cell lymphotropic virus type III (HTLV-III) core antigens: synthesis in Esche- richia coli and immunoreactivity with human sera. DNA 5:93-99, 1986; Chang, T.W. , Kato, I., McKinney, S., Chanda, P., Barone, A.D. , Wong-Staal, F., Gallo, R.c. and Chang, N.T. : Detection of antibodies to human T-cell lymphotropic virus-Ill (HTLV-III) with an immuno¬ assay employing a recombinant Escheria coli-derived viral antigenic peptide. Bio/Technology 3:905-909, 1985). The specificity and sensitivity of these assays are good, but not 100% (Chang, T.W. et al . ibid; Dein- hardt, F., Eberle, J. and Gϋrtler, L. : Sensitivity and specificity of eight commercial and one recombinant anti-HIV ELISA tests. Lancet: 40, 1987). The envelope protein gpl20 varies between isola- tes (Wong-Staal, F. et al, ibid; Weiss, R.A. , Clapham, P.R., Weber, J.N., Dalgleish, A.G., Lasky, L.A. and Berman, P.W.: Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324:572-575, 1986) and consequently peptides from them are not usually recommendable as ELISA antigens. Antibodies to gp41 have instead been considered the most sensitive diagnostic criterion of HIV infection (Sarngadharan, M.G. , et al, ibid; Schϋpbach, J. , et al, ibid). gp41 contains regions that are well conser¬ ved between various isolates. Antibodies to p24 disap¬ pear with progessive disease (Lange, J.M.A. , Paul, D.A. , Huisman, H.G. , de Wolf, F. , van der Berg, H. , Coutinho, R.A. , Danner, S.A., van der Noordaa, J. and Goudsmit, J. : Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. British. Med. J. 293:1459-1461, 1986) but are the ones which appear early. Regarding known antibody responses, a combination of measuring anti p24 and anti gp41 should therefore be the most reliable for all circumstances. Performing Wes-tern blot is time consuming and expensive. To produce reliable antigens for use in ELISA seems preferable. No single assay has so far obtained 100% specificity and sensitivity (Deinhardt, F., et al, ibid; Lange, J.M.A. , et al, ibid). Recently, Gnann, J.W. , et al (Journal of Virology, Aug. 1987, p. 2639-2641) identified a 12-amino-acid peptide derived from gp41 of HIV, that was recognized by 100% of the sera from HIV-infected sera. The descri¬ bed peptide contained two cystein residues, and the authors stated that they provide evidence that disulfide bond formation plays a key role in the antigenic confor- mation of the epitope. However, no such evidence was presented. The authors assumed that the peptide had cyclized spontaneously, and they attempted to prove it by reducing the alleged disulfide bond, but they failed. Instead they synthesized another 12-amino-acid peptide in which they had substituted serine for one of the cysteines, and when this was tested it reacted with only 2 of 22 HIV-positive test sera. The authors conclude that the presence of both cysteine residues is essential for the antigenic conformation of the epitope, possibly via formation of disulfide bonds. They have not proved that they had a disulfide bond in the investigated peptide, what they have done is to show that cysteine is better than serine in the specified position of said peptide. The existence of two cysteines in a peptide is not equivalent to a cyclic structure. The cyclization demands a defined chemical step, namely oxidation, and the result can be method dependent. If spontaneous cyclization occures it is often incomplete and accompanied by polymerization, In primary HIV disease, antibody tests may be negative during a period (Marlink, R.G., Allan, J.S., McLane, M.F., Essex, M. , Anderson, K.C. and Groopman, J.E. : Low sensitivity of ELISA testing in early HIV Infection. The New Engl. J. Med. 315:1549, 1986). The development of a single rapid, sensitive and specific assay for detecting antibodies to HIV, also at an early stage of infection, is most desirable. Description of the invention The present invention provides i.a. a rapid, sensitive and specific assay for detection of anti¬ bodies induced by a HIV. in one aspect of the invention there is provided an artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine residues which has been formed by a chemical oxidation step. It is belie¬ ved that this stabilization of the peptide by a sulphur bridge between two cysteine residues is responsible for the useful properties of the peptide, such as an enhancement of the antibody binding activity, as well as the chemical stability of the final product. The artificial peptide includes at least two systeine residues, which are cyclized to form a sul¬ phur bridge. The two cysteine residues which are linked together may have one or more amino acid residues comprising an epitope between themselves, such as 2 to 10 residues, e.g. 5 residues. If the artificial peptide according to the invention includes more than two cysteine residues, still only one sulphur bridge between two cysteine residues is formed by a chemical oxidation step. In a preferred embodiment of this aspect of the invention there is provided an artificial peptide, which is chosen from the group consisting of the peptide having the modified amino acid sequence H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- I I thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; I I the peptide having the modified amino acid sequence H-Lys-Ala-Cys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg- \ -Cys-Ser-Ser-Asn-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg-Cys-; 1 \ the peptide having the modified amino acid sequence H-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly- -Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-NH 2 I I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; I I the peptide having the modified amino acid sequence H-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-NH- 1 I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; I 1 the peptide having the modified amino acid sequence H-Asn-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr- I I -Thr-Val-Pro-Trp-Val-Asn-Asp-Ser-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-; the peptide having the modified amino acid sequence H-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr- I I -Val-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Glu-Val-Cys-; J the peptide having the modified amino acid sequence H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- ^ -Cys-Ala-Phe-Arg-Gln-Val-Cys-NH- 1 I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-, and I I the peptide having the modified amino acid sequence H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arα-Gln-Val-Cys-His-Thr-Thr-Val-NH i : i and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-. I I At present, the most preferred artificial peptide according to the invention is H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- I 1 -Ala-Val-Pro-Trp-Asn-Ala-Ser-NH 2 . In another aspect of the invention there is pro¬ vided an artificial antigen which reacts with antibodies induced by a HIV, which antigen mainly consists of an artifical peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epi¬ tope, and further having a sulphur bridge between said two cysteine residues which has been formed by a chemical oxidation step. in the specification and claims the expression "antigen mainly consists of an artificial peptide" indi¬ cates that the ability of the antigen to react with antibodies derives from the artificial peptide. In a preferred embodiment of this aspect of the invention there is provided an artificial antigen which reacts with antibodies induced by a HIV, which antigen mainly consists of a preferred artificial peptide accor¬ ding to the invention, exemplified above. The artificial antigens according to the invention can be immobilized or coupled to a carrier, such as mineral carriers, e.g. aluminium hydroxide, calcium phosphate, etc., plastic surfaces, e.g. microplates, beads, etc., proteins, such as bovine serum albumin or an immunizing component, such as keyhole limpet hae- mocyanin. Even though the artificial antigens according to the invention so far only have been used as diagnostic antigens to detect antibodies induced by a HIV, in a sample of body fluid, it is believed that they can be used as immunizing components in vaccine compositions against a HIV. When a peptide (Example I) of the inven- tion (without carrier) was injected into apes, antibodies directed against the C-terminal portion of the peptide were elicited. Thus, a further aspect of the invention provides a vaccine composition, which comprises as an immunizing component, at least one antigen selected from artifi¬ cial antigens according to the invention, together with a nontoxic pharmaceutically acceptable carrier and/or diluent. In yet another aspect of the invention there is provided a method of detecting antibodies induced by a HIV in a sample of body fluid, wherein said sample is subjected to an immunoassay and an artificial antigen according to the invention is used as a diagnostic anti¬ gen. The sample of body fluid can be urine, saliva, tear fluid, milk, serum or blood. The immunoassay in which the artificial antigens according to the invention can be used as diagnostic antigens is any immunoassay of choice, such as enzyme- linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunodiffusion or immunoelectrophoreses (IE). In a preferred embodiment of this aspect of the invention ELISA is used as the immunoassay of choice. In a further aspect of the invention there is pro¬ vided a diagnostic immunoassay kit for the detection of antibodies induced by a HIV in a sample of body fluid, wherein an artificial antigen according to the invention is included as a diagnostic antigen. Depending on the immunoassay to be used, the kit will comprise other items, such as a positive standard serum sample, a nega- tive standard serum sample, in the case of ELISA an enzyme conjugate and optionally a substrate for the enzyme conjugate, and also optionally buffer solution (s) and/or washing solution(s). Optionally all the reagents in the kit are contained in separate sealed test tubes or vials marked with specific labels. Synthesis of the artificial peptides of the invention The artificial peptides of the invention can be produced by any known method of producing a linear peptide sequence, such as cloning, degradation, coupling of one amino acid residue to the next one in liquid phase or coupling the amino acids to one another starting with a solid phase (resin) to which the C-terminal of the first amino acid is coupled, whereupon the C-terminal of the next amino acid is coupled to the N-terminal of the first amino acid, etc. , finally releasing the built-up peptide from the solid phase (so-called Merri- field synthesis). Once the appropriate linear peptide sequence is ready, it is subjected to a chemical oxidation step in order to cyclize two cysteine residues thereof, whereby a sulphur bridge is formed between the cysteine residues. General description of synthesis In the examples below, all peptides were synthe¬ sized on an Applied Biosystems 430A Peptide Synthesizer using a double coupling pro.gram with termination step after the second coupling. The resin used was of 4-methyl- benzh dr lamine type with theoretical loading of 0.66 meq/g (Peptides International, Louisville, KY, USA). The final product of the synthesis was dried in vacuo over night. After drying the peptide-resin was suspended in methanol (70 ml) and saturated with ammonia. The mixture was placed in pressurized steel vessel and left over night with magnetic stirring. The resin was then separated by filtration, washed several times with metha¬ nol and thoroughly dried in vacuo. The peptide was then cleaved from the resin by treatment with liquid hydrogen fluorid in the presence of anisole and eth l-methyl-sul- fide as scavangers (HF:anisole:EMS - 10:05:05). After removal of hydrogen fluoride by evaporation the residue was suspended in ethyl acetate (100 ml) and filtered. The solid was washed on filter with additional ethyl acetate (3x100 ml) and the cleaved peptide extracted with acetic acid (100 ml). The extract was promptly diluted to the volume of 2 dm with 20% acetic acid in methanol and treated with 0.1 M solution of iodine in methanol until the faint brown colour persisted. Then the Dowex 1x8 ion exchanger in acetate form was added (3 g) (Bio-Rad, Richmond, CA) and the mixture was filtered. The filtrate was evaporated and the residue freeze-dried from 1% acetic acid in water. The product was then purified by reversed phase liquid chromatography on a column filled with Vydac 20-25 μ (Separation Group, CA) in a suitable system containing acetonitrile in 0.1% trifluoroacetic acid water solution. The samples collected from the column were analyzed by analytical HPLC - Varian 5500 (Sunnyvale, CA) equipped with Bondapak C18 column (Millipore, Milford, Mass.). Fractions con¬ taining pure substance (>99,5%) were pooled, the solvent was evaporated and the product freeze-dried from 1% acetic acid in water. The final HPLC analysis was per¬ formed on ready product and the structure of the peptide was confirmed by amino acid analysis and FAB-MS (Fast atom bombardment spectrometry) . All amino acids used during the synthesis were protected with tert-butoxycarbonyl group at α-amino- function. The side chain protections used were as follows: Ser(BZL), Thr(BZL), Tyr(2-BrCbz) , Lys(2-ClCbz) , Orn(Cbz), Asp(BZL), Glu(BZL), Arg(Tos), Cys(Mob). Amino acid derivatives were delivered by Bachem AG, Switzerland. EXAMPLE I (The sequence corresponds to a sequence found in HIV-1- -gp-41) H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- -Ala-Val-Pro-Trp-Asn-Ala-Ser-NH 2 The peptide was prepared according to the general description of synthesis. Purity - 99.9% according to HPLC (36% acetonitrile in 0.1% trifluoroacetic acid, retention time 6.79 min at 2 ml/min; detection at 223 nm) The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE II (The sequence corresponds to a sequence found in HIV-1- -gpl20, modified by insertion of the cysteine residue located closer to the C-terminal.) H-Lys-Ala-Cys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg- -Cys-Ser-Ser-Asn-NH 2 The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE III (The sequence corresponds to a sequence found in HIV-1- -gp-41) H-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly- -Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-NH I f The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE IV (The sequence corresponds to a sequence found in HIV-1- -gp-41) H-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-NH- I { The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE V (Reference) (The sequence corresponds to a sequence found in HIV-1- -gp-41) H-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-Val-Pro-Trp-Asn- -Ala-Ser-NH 2 The peptide was prepared according to the general description of synthesis, with the exception of the oxidation step with iodine. Purity >98.5%(HPCL) . The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE VI (Reference) (The sequence corresponds to a sequence found in HIV-1- -gp-41) H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- -Ala-Val-Pro-Trp-Asn-Ala-Ser-NH 2 The peptide was prepared according to the general description of synthesis, with the exception of the oxidation step with iodine. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE VII (The sequence corresponds to a sequence found in HIV-2- -gp41) H-Asn-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr- . i I -Val-Pro-Trp-Val-Asn-Asp-Ser-NH 2 The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE VIII (The sequence corresponds to a sequence found in HIV-2 transmembrane) H-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr- -Val-NH 2 The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE IX (The sequence corresponds to a sequence found in HIV-2 transmembrane) H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-NH- I I The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. EXAMPLE X (The sequence corresponds to a sequence found in HIV-2 transmembrane) H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr-Val-NH 2 The peptide was prepared according to the general description of synthesis. The structure was confirmed by amino acid analysis and by FAB-MS. Detection of antibodies induced by HIV in blood samples; For the detection of antibodies induced by HIV in blood samples use was made of ELISA. (Engvall, E. and Perlmann, P. : Enzyme-linked immunosorbent assay (ELISA). Ill Quantification of specific antiboides by enzyme labelled anti-immunoglobulin in antigen-coated tubes. J. Immunol. 109.129-135,1972). Materials: Plates: Nunc 96 F, Roskilde, Denmark Conjugate: HRPO rabbit anit-human Ig, Dakopatts, Glostrup, Denmark Buffers: Carbonate buffer: 0.05 M sodium carbonate buffer, pH approx. 9.5. Buffer A: Phosphate buffered saline (PBS) without Ca and Mg , and with 0.5% bovine serum albumin " (BSA) and 0.05% Tween 20 + 20% fetal calf serum (FCS). Can be stored at 4°C for 1-3 days. OPD buffer: 0.0347 M citric acid, 0.0667 M Na 2 HP0 4 , pH 5.5. Can be stored 1 month. OPD tablets, Dakopatts, Glostrup, Denmark. Washing solution: 0.9% NaCl with 0.05% Tween 20. Methods: Coating: A solution of the coating antigen (test peptide), 5 μg to 20 μg per ml, is made in carbonate buffer. 100 μl of the solution is added to each well of stripes or of 96-well microplates. The adsorption takes place over night, 18 hrs, at room temperature. The coated plates can be stored with their contents in 4°C until use. Serum assay: 1. Empty and wash the plate 4 times with washing solution. 2. Add 100 μl of serum diluted 1:100 in buffer A. 3. Add 100 μl of just buffer A to one well; this well serves as a blank. 4. Incubate 60 min at 37°C. (Dilute the conjugate during this period, see 6). 5. Wash 4 times with washing solution. Empty. 6. Add 100 μl of a conjugate, e.g. HRPO rabbit anti-human IgG,IgA,IgM diluted 1:15 000 in buffer A (for instance 5 μl added to 0.75 ml, dilute this 1:100). 7. Incubate at 37°C for 30 min. (Prepare substrate solution during this period, see 9) . 8. Wash 4 times with washing solution. Empt . ■ 9. Add 100 μl OPD substrate (6 tablets/10 ml OPD buffer. Use a clean vessel. 15-20 min are needed to dissolve the tablets. When dissolved, add 4 μl H 2 0 2 / 10 ml) . 10. Incubate 30 min at toom temperature. Stop the reaction with 100 μl 2.5 M H 2 S0 4 . 11. Read plate at 490 nm. Negative values should be below 0.250. Using the above described materials and methods the following materials were tested as diagnostic antigens (coating antigens) for the detection of antibodies induced by HIV in serum samples from infected patients: A. A recombinant protein gp 160 (expressed in Baculo- -virus in insect cells). Received from Repligen Corp. Cambridge, Mass., USA. .- B. A recombinant polypeptide p 121 (with conserved region of gp 41, cloned in E. coli) received from Repligen Corp. Cambridge, Mass., USA. C. A synthetic peptide described in Example V (Refe¬ rence) of this specification (only one cysteine resi¬ due, no cyclization) . D. An artificial peptide according to the invention described in Example I of this specification. E. An artificial peptide according to the invention described in Example II of this specification. Serum samples from HIV infected human patients and from non-infected humans were tested. Their serological status had been confirmed by Western blot. The results were as follows: HIV antibody ELISA From the above results it is evident that the tested artificial peptides according to the invention (D. and E. ) exhibits both excellent sensitivity and excellent specificity. In the same way the following additional artificial peptides according to the invention were tested, namely F. An artificial peptide described in Example III of this specification, G. An artificial peptide described in Example IV of this specification, H. An artificial peptide described in Example VIII of this specification, I. An artificial peptide described in Example IX of this specification, and J. An artificial peptide described in Example X of this specification. The results were as follows: HIV antibody ELISA Even though these peptides (F.-J.) are not as good as the peptides D. and E. they show a good reactivity with' antibodies induced by HIV. Comparison of seroreactivity between a cyclic and a linear peptide Using the above described materials and methods (ELISA) the cyclic peptide of Example I and the corre- sponding linear peptide of Example VI were tested at different serum dilutions. The results were as follows: HIV antibody ELISA HIV_serogositive i _n=66 Number of serum dilu¬ Number of positive tions having Amount of Serum reactions with peptide highest absor- peptide dilution bancy values cyclic linear cyclic linear 5 μg 1/20 66 66 1/100 61 60 118 78 1 500 27 19 10 μg 166 30 20 μg 129 67 Total number of reactions 467 428 413 175 HIV_serone2ative i _n=22 5 μg 1/20 2 11 10 μg 1/20 5 2 20 μg 1/20 1 _1 Total number of reactions 14 The results of the above comparison illustrate the advantage of the cyclic peptide as compared to the corresponding linear peptide. Both peptides give posi¬ tive results with all sera at the lowest serum dilution. However, the reactions decrease rapidly with the linear peptide, while the cyclic peptide is capable of keeping its configuration for positive antibody reactivity (see the above Table, columns 3 and 4). This is a necessary characteristic to be able to detect with certainty sera having low antibody titres. A direct comparison of the absorbancy values in ELISA shows that the cyclic peptide is by far superior to the linear one (see the above Table, columns 5 and 6 The relationship is the reverse when it comes to the antibody-negative sera. The specificity is 100% for both peptides, but the background values are higher for the linear peptide. This indicates advantages in both specific and- non-specific reactions for the cyclic peptide.

Claims: CLAIMS 1. An artificial peptide having an amino acid se¬ quence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope , c h a r a c t e r i s e d in that the peptide has a sulphur bridge between said two cys¬ teine residues which has been formed by a chemical oxi ¬ dation step. 2. An artificial peptide according to claim 1, c h a r a c t e r i s e d in that it is chosen from the group consisting of the peptide having the modified amino acid sequence H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- I L -Ala-Val-Pro-Trp-Asn-Ala-Ser-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; I I the peptide having the modified amino acid sequence H-Lys-Ala-Cys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg- I -Cys-Ser-Ser-Asn-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg-Cys-; 1 the peptide having the modified amino acid sequence H-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly- -Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-NH 2 I I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; the peptide having the modified amino acid sequence H-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-NH^, i I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; the peptide having the modified amino acid sequence H-Asn-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr- 1 I -Thr-Val-Pro-Trp-Val-Asn-Asp-Ser-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-; i : i the peptide having the modified amino acid sequence H-Ser-Trp-Gly- C ys- A la-Phe- A rg-Gln-Val-Cys-His-Thr-Thr- I J -Val-NH, and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Glu-Val-Cys-; I I the peptide having the modified amino acid sequence H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-NH I I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-, and I I the peptide having the modified amino acid sequence H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr-Val-NH 2 1 I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-. 1 / 3. An artificial antigen which reacts with anti¬ bodies induced by a HIV, c h a r a c t e r i s e d in that the antigen mainly consists of an artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine resi ¬ dues which has been formed by a chemical oxidation step. 4. An artificial antigen according to claim 3, c h a r a c t e r i s e d in that the antigen mainly consists of an artificial peptide chosen from the group consisting of the peptide having the modified amino acid sequence H-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr- J -Ala-Val-Pro-Trp-Asn-Ala-Ser-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; the peptide having the modified amino acid sequence H-Lys- A la- C ys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg- I . -Cys-Ser-Ser-Asn-NH 2 and peptides having a shorter sequence thereof including the modified sequence - C ys-Tyr-Ala-Pro-Pro-Ile-Ser-Gly-Gln-Ile-Arg-Cys-; i i the peptide having the modified amino acid sequence H-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly- -Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-NH 2 1 : 1 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; I I the peptide having the modified amino acid sequence H-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ser-Gly-Lys-Leu-Ile-Cys-; \ I the peptide having the modified amino acid sequence H- A sn-Ser-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr- 1 I -Thr-Val-Pro-Trp-Val-Asn-Asp-Ser-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-; I I the peptide having the modified amino acid sequence H- S er-Trp- G ly- C ys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr- i I -Val-NH 2 and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Glu-Val-Cys-; I I the peptide having the modified amino acid sequence H-Tyr-Leu-Gln- A sp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-NH 9 I I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Val-Cys-, and 1 1 the peptide having the modified amino acid sequence H-Tyr-Leu-Gln-Asp-Gln-Ala-Arg-Leu-Asn-Ser-Trp-Gly- -Cys-Ala-Phe-Arg-Gln-Val-Cys-His-Thr-Thr-Val-NH„ I I and peptides having a shorter sequence thereof including the modified sequence -Cys-Ala-Phe-Arg-Gln-Va1-Cys-. 1 I 5. An artificial antigen according to claim 3 or 4, c h a r a c t e r i s e d in that it has been immo¬ bilized or coupled to a carrier. 6. A method of detecting antibodies induced by a HIV in a sample of body fluid, wherein said sample is subjected to an immunoassay, c h a r a c t e r i ¬ s e d in that an artificial antigen according to any one of claims 3-5 is used as a diagnostic antigen. 7. A method according to claim 6, wherein said sample is subjected to enzyme-linked immunosorbent assay (ELISA) c h a r a c t e r i s e d in that an artifi¬ cial antigen according to any one of claims 3-5 is used as a diagnostic coating antigen. 8. A diagnostic immunoassay kit for the detection of antibodies induced by a HIV in a sample of body fluid, c h a r a c t e r i s e d in that it comprises as a diagnostic antigen an artificial antigen according to any one of claims 3-5. 9. A diagnostic immunoassay kit according to claim 8, c h a r a c t e r i s e d in that it additionally comprises a positive standard serum sample, a negative standard serum sample, an enzyme conjugate, optionally a substrate for the enzyme conjugate, and optionally buffer solution(s) and/or washing solution(s) . 10. A vaccine composition, c h a r a c t e r i ¬ s e d in that it comprises as an immunizing component, at least one antigen selected from the artificial anti- gens according to any one of claims 3-5, together with a nontoxic pharmaceutically acceptable carrier and/or diluent.

Inventors: RUDEN ULLA, TROJNAR JERZY, WAHREN BRITA, RUDEN, ULLA, TROJNAR, JERZY, WAHREN, BRITA
Applicants: FERRING AB
Application year: 1988
Main classification: C07K7
IPC codes: A61K38, A61K39, A61P31, C07K1, C07K7, C07K14, C07K17, G01N33